The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patients (pts) with R/R large B-cell lymphoma (LBCL) treated with lisocabtagene maraleucel (liso-cel) nonconforming product (NCP) under the Expanded Access Protocol (EAP).
 
Brian G. Till
Consulting or Advisory Role - MustangBio; Proteios Technology
Research Funding - BMS Brazil (Inst); MustangBio (Inst)
Patents, Royalties, Other Intellectual Property - MustangBio
 
Caron Alyce Jacobson
Honoraria - Abbvie; Abintus Bio; ADC Therapeutics; Appia Bio; AstraZeneca; Bristol-Myers Squibb; Caribou Biosciences; Celgene; Daiichi Sankyo/UCB Japan; ImmPACT-Bio; Ipsen; Janssen; Kite/Gilead; Miltenyi Biomedicine; MorphoSys; Novartis; Sana; Synthekine
Consulting or Advisory Role - Abbvie; Abintus Bio; ADC Therapeutics; Appia Bio; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/UCB Japan; ImmPACT-Bio; Ipsen; Janssen; Kite/Gilead; Miltenyi Biomedicine; MorphoSys; Novartis; Sana; Synthekine
Research Funding - Kite, a Gilead company; Pfizer
 
Maria Lia Palomba
Stock and Other Ownership Interests - Notch Therapeutics (I); Pluto Immunotherapeutics (I); Seres Therapeutics (I)
Honoraria - ceramedix (I); Frazier Healthcare Partners (I); Garuda Therapeutics (I); GlaxoSmithKline (I); Lygenesis (I); Nektar (I); Notch Therapeutics (I); Pluto Immunotherapeutics (I); Rheos Medicines (I); Seres Therapeutics (I); thymofox (I)
Consulting or Advisory Role - BeiGene; bristol m; Cellectar; MustangBio; Seres Therapeutics (I); Synthekine
Research Funding - Seres Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Intellectual Property Rights (I); Juno intellectual property rights (Inst)
 
Jeremy S. Abramson
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb/Celgene; Janssen; Kite, a Gilead company; Regeneron
Consulting or Advisory Role - Abbvie; ADC Therapeutics; Alimera Sciences; AstraZeneca; BeiGene; Bluebird Bio; Bristol-Myers Squibb; C4 Therapeutics; Caribou Biosciences; Celgene; Cellectar; Century Therapeutics; EMD Serono; Epizyme; Genmab; Incyte; Interius Biotherapeutics; Janssen; Karyopharm Therapeutics; Kite, a Gilead company; Kymera; Lilly; MorphoSys; MorphoSys; MustangBio; Novartis; Ono Pharmaceutical; Roche/Genentech; Seagen; Takeda
Research Funding - Bristol-Myers Squibb/Celgene (Inst); Cellectis (Inst); Merck (Inst); MustangBio (Inst); Regeneron (Inst); Seagen (Inst)
 
Jon Arnason
Honoraria - Bristol-Myers Squibb/Celgene/Juno
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Celgene/Juno
 
Frederick L Locke
Honoraria - Aptitude Health; ASH; BioPharma Services; Clinical Care Options Oncology; Communications CARE Education,; Imedex; Society for Immunotherapy of Cancer
Consulting or Advisory Role - A2 Biotherapeutics; Amgen; Bluebird Bio; Bristol-Myers Squibb; Calibr; Caribou Biosciences; EcoR1 Capital; Gerson Lehrman Group; Iovance Biotherapeutics; Janssen; Kite Parma; Legend Biotech; Novartis; Pfizer; Sana; Umoja Biopharma
Research Funding - 2seventy bio (Inst); Alimera Sciences (Inst); Bluebbird Bio (Inst); Bristol-Myers Squibb (Inst); CERo Therapeutics (Inst); Kite, a Gilead Company (Inst); Leukemia and Lymphoma Society Scholar in Clinical Research (PI: Locke); National Cancer Institute (R01CA244328 MPI: Locke; P30CA076292 PI: Cleveland); NOvartis (Inst)
Patents, Royalties, Other Intellectual Property - Moffitt Cancer Center (Inst)
Travel, Accommodations, Expenses - ASH; Kite, a Gilead Company
 
Paolo Fabrizio Caimi
Honoraria - Gilead Sciences
Consulting or Advisory Role - ADC Therapeutics; BeiGene; Bristol-Myers Squibb/Celgene; Genentech; Genmab; Incyte; Kite, a Gilead company; Lilly; MEI Pharma; Novartis; Takeda
Research Funding - Abbvie; ADC Therapeutics; Genentech; Luminary Therapeutics
Patents, Royalties, Other Intellectual Property - XaTEC patent holder (I)
(OPTIONAL) Uncompensated Relationships - Abcon Therapeutics; Luminary Therapeutics
 
Natalie Sophia Grover
Stock and Other Ownership Interests - Sangamo Therapeutics
Honoraria - ADC Therapeutics; Bristol Myers Squibb Foundation; Caribou Biosciences; Genentech; Kite, a Gilead company; Novartis; Ono Pharmaceutical; Seagen
Consulting or Advisory Role - Regeneron
Research Funding - Tessa Therapeutics
 
Reem Karmali
Honoraria - Bio Ascend; Prime Oncology
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Celgene/Juno; Calithera Biosciences; EUSA Pharma; Genentech/Roche; Gilead Sciences; Lilly; Miltenyi Biotec
Speakers' Bureau - AstraZeneca; BeiGene; MorphoSys/Incyte
Research Funding - BeiGene (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Miltenyi Biotec (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Prime Oncology
 
Hyung C. Suh
No Relationships to Disclose
 
Stephen J. Schuster
Consulting or Advisory Role - Acerta Pharma/AstraZeneca; BeiGene; Celgene; Genentech/Roche; Incyte; Janssen; Legend Biotech; Loxo; MorphoSys; MustangBio; Novartis; Regeneron
Research Funding - Abbvie (Inst); Adaptive Biotechnologies (Inst); Celgene (Inst); DTRM (Inst); Genentech/Roche (Inst); Incyte (Inst); Juno Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent Combination Therapies of CAR and PD-1 Inhibitors (via University of Pennsylvania with royalties to Novartis)
 
Mecide Meric Gharibo
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Catherine Balint
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb; Celularity
 
Trias Rakhmawati
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Veronica Jude
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Loretta J. Nastoupil
Honoraria - ADC Therapeutics; AstraZeneca; Bristol-Myers Squibb; Caribou Biosciences; Daiichi Sankyo/UCB Japan; Epizyme; Genentech/Roche; Genmab; Gilead Sciences; Incyte; Ipsen; Janssen Oncology; Morphosys; Novartis; Takeda
Consulting or Advisory Role - Interius Biotherapeutics; SIRPant Immunotherapeutics
Research Funding - Allogene Therapeutics; Bristol-Myers Squibb/Celgene; Caribou Biosciences; Daiichi Sankyo/UCB Japan; Daiichi Sankyo/UCB Japan; Epizyme; Genentech/Roche; Genmab; Gilead Sciences; IgM Biosciences; Ipsen; Janssen Biotech; Novartis; Takeda
Travel, Accommodations, Expenses - Genentech/Roche